Evidence map›Paper›PMID 28649781›Full record

ArticleJournal of clinical laboratory analysis2018

Anti-D reagents should be chosen accordingly to the prevalence of D variants in the obstetric population.

Jelena Lukacevic Krstic, Slavica Dajak, Jasna Bingulac-Popovic, Vesna Dogic, Jela Mratinovic-Mikulandra

Open access · bronzeAbstract read
In one paragraph

Article in Journal of clinical laboratory analysis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Transfusion support for a woman withImmunohematology · 2022
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jelena Lukacevic KrsticDepartment of Transfusion Medicine, Split University Hospital Center, Split, Croatia.ORCID http://orcid.org/0000-0003-3027-0274
Slavica DajakDepartment of Transfusion Medicine, Split University Hospital Center, Split, Croatia.
Jasna Bingulac-PopovicDepartment of Molecular Diagnostics, Croatian Institute of Transfusion Medicine, Zagreb, Croatia.
Vesna DogicDepartment of Molecular Diagnostics, Croatian Institute of Transfusion Medicine, Zagreb, Croatia.
Jela Mratinovic-MikulandraDepartment of Transfusion Medicine, Split University Hospital Center, Split, Croatia.
University of Split · HRCroatian Institute of Transfusion Medicine · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundResolving ambiguous results of D antigen typing is crucial for appropriate and rational administration of anti-D immunoprophylaxis and transfusion practice in obstetric population. The aim of the study was to establish selection criteria of anti-D reagents for our population.

methodsA total of 12 689 samples from primiparous women in Split-Dalmatia County, Croatia, were typed for RhD antigen during the period of 5 years. Ambiguous results were submitted to additional serologic investigation and genotyping. RHD genotyping was performed by commercial genotyping kits (Ready Gene weak D

resultsThe prevalence of D variants was 0.42% (95% CI 0.31; 0.53). The most common partial D variant was D Va (RHD*05.05), with the prevalence of 0.08% (95% CI 0.03; 0.13). All weak D variants were weak D types 1, 2 and 3 (RHD*weak D type 1, RHD*weak D type 2, RHD*weak D type 3). Weak D samples were distinguishable from partial D in routine typing due to the difference in reactivity of partial D samples with clones D7B8 and RUM-1. Cell line RUM-1 gives weak or negative reactions with partial DVa category.

conclusionThe most common partial D variant in our population is DVa. It is recommended to use cell lines which do not strongly agglutinate DVa variant in routine RhD typing. The appropriate choice of reagents will enable the serology methods to recognize the cases in which RHD genotyping is required.

Indexed as

Blood Grouping and CrossmatchingRh-Hr Blood-Group SystemCroatiaFemaleGenotypeGenotyping TechniquesHumansPregnancyPrevalenceRho(D) Immune GlobulinRh-Hr Blood-Group SystemRHO(D) antibodyRho(D) Immune Globulinanti-D reagentsD variantsobstetricpopulation

Identifiers

PMID28649781
PMCPMC6817088
OpenAlexW2682127267

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.